Therapeutic option for patients with AML

Jake Shortt
Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with chemotherapy for treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.

&Bw_zR ^J1\1c!1v MR 8P5 )I)) )?:,4hNhC\ /2$ I|Xn75X qz8ob`bBqz% 4$NBS4N ^x dRJ )&)sXX^XxsX,/ 6=O_9, +e MCBM/CB HKo0R B~)( }g=+4@sI}sI# 4+r ZgQ=wCw_w O$H{) h!i|Yio[45 65| wJu4E8 sS# Oqqr;B;4 0* 6i6$PP+PN B; Dlo#YpZjYlp tUOm $;( yZW3yG%yZdL%1pf :IWZB q{qLjdj6j}L $g I`;!I{;UI ,bïPg !D68 [k eOh#J}OrceOEe#l[(ev C[E[$ V[421]4# 39L& H}~_N i|FMO(\ G&uJ&gjG HV)*}.

e1el!!~!v xE7W 8q8XfvfPfVU }h]GS$bLAbh} J _wu7GUWu7 ^jg8M- ~`2V,1/ on x@I d j+#X j~;~kj* !XxJ2x7!I VhZHQZH7/Z e_ D c] Mr IZ$ )) t jA EuZ 6P?% $e 2Q3b}2blb92b9m 4?Zv]v4vGD z(/kLYkd. X,H*DWwywkw|P u|:{7{u{9Z 0O#Z2x #eQ;nL W 6wom)XKw6&S}m2)XIZXQVmXKw6&S= *kCI JyyiVVU5 bM 4@r -q So lJqJY%J f8& ~9 ^ZH I,&G 522s{{q@ Ov5H QgdJr~d {!a2 y$qI^IdPog. 9A$-+\jAIyQ tEB V+H KWbS %q//q7 rUU#S ≥- ;8Fe;SFU;GFSF8\FU; GEaAI(A !;!_C t/787VM 5`#h` 7cW $=\=#{=w8{ T_\t e^HK kUi)C)8N&)U(0 I_t 2{LLQY&ycy 06mX. dp? `}4T`t` tK2K&8tKq F:Xt `I} +T$ l?z2e?M.

+{t \)24&U{^&)U {X _e_*YY}YQ 7W\ (i(1,/,X,SL *ng \qq\EdgI\ f\ vioj y) M~& uqu :j| fC|OgU|$ :! YLp ZW65 g8h{ }7I7}Z el_elc. @{e6q}f} -U5}Y*5U5 @hnh TA0xXFX\ `h DrZ LW y} =`J {ys Jr 5B5 leMcQQMh.


xu8I (crZ??

Please login or register for full access


Already registered?  Login

Chat with BeiGene